

## Datasheet: HCA211

**BATCH NUMBER 152019**

<b>Description:</b>	HUMAN ANTI USTEKINUMAB
<b>Specificity:</b>	USTEKINUMAB
<b>Other names:</b>	Stelara®
<b>Format:</b>	Purified
<b>Product Type:</b>	Monoclonal Antibody
<b>Clone:</b>	AbD17829_hlgG1
<b>Isotype:</b>	IgG1
<b>Quantity:</b>	0.1 mg

## Product Details

### Applications

This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit [www.bio-rad-antibodies.com/protocols](http://www.bio-rad-antibodies.com/protocols).

	Yes	No	Not Determined	Suggested Dilution
ELISA	▪			

Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.

<b>Product Form</b>	Human IgG1 antibody selected from the HuCAL® phage display library and expressed in a human cell line. This antibody is supplied as a liquid.
<b>Preparation</b>	Purified IgG prepared by affinity chromatography on Protein A from tissue culture supernatant
<b>Buffer Solution</b>	Phosphate buffered saline
<b>Preservative Stabilisers</b>	0.01% Thiomersal
<b>Approx. Protein Concentrations</b>	Antibody concentration 0.5 mg/ml
<b>Immunogen</b>	Ustekinumab

<b>Specificity</b>	<p><b>Human Anti-Ustekinumab Antibody, clone AbD17829_hIgG1</b> is a paratope specific, anti-idiotypic antibody that specifically recognizes the monoclonal antibody drug ustekinumab and inhibits binding to its target.</p> <p>Clone AbD17827_hIgG1 is a fully human recombinant monoclonal antibody with IgG1 isotype and is suitable as a surrogate positive control or calibrator in an anti-drug antibody (ADA) assay.</p> <p>Ustekinumab (Stelara) is a fully human monoclonal antibody drug (IgG1/kappa) that has been approved in US, Canada, and Europe for the treatment of plaque psoriasis and psoriatic arthritis. The FDA approved the medication for the treatment of moderate-severe Crohn's disease in 2016. The drug blocks interleukin IL-12 and IL-23 by binding with high affinity and specificity to the p40 subunit, preventing the binding of these two cytokines to T-lymphocytes, and thereby disrupting the proinflammatory pathway.</p> <p><a href="#">View a summary of all anti-ustekinumab antibodies</a></p>
<b>Affinity</b>	The monovalent intrinsic affinity of AbD17829 was measured as $K_D = 2.8$ nM by real time, label free molecular interaction analysis on immobilized ustekinumab.
<b>ELISA</b>	<p>This product may be used in an indirect ELISA or as a detection antibody when conjugated to HRP in a bridging ELISA together with AbD18334 (<a href="#">HCA209</a>) as the capture reagent. Conjugation of this antibody to HRP can be undertaken using a Lynx Rapid HRP conjugation kit, these kits may be purchased from Bio-Rad.</p> <p>Protocol: <a href="#">PK bridging ELISA to measure free drug</a></p> <p>Protocol: <a href="#">ADA bridging ELISA</a></p>
<b>Storage</b>	<p>Store at +4°C or at -20°C if preferred.</p> <p>Storage in frost-free freezers is not recommended.</p> <p>This product should be stored undiluted. Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use.</p>
<b>Guarantee</b>	12 months from date of despatch
<b>Acknowledgements</b>	Sold under license of U.S. Patents 6753136, 7785859 and 8273688 and corresponding patents. This antibody was developed by Bio-Rad, Zeppelinstr. 4, 82178 Puchheim, Germany.
<b>Health And Safety Information</b>	Material Safety Datasheet documentation #10094 available at: <a href="https://www.bio-rad-antibodies.com/SDS/HCA211">https://www.bio-rad-antibodies.com/SDS/HCA211</a> 10094
<b>Licensed Use</b>	For in vitro research purposes and for commercial applications for the provision of in vitro testing services to support preclinical and clinical drug development. Any re-sale in any form or any other commercial application needs a written agreement with Bio-Rad.
<b>Regulatory</b>	For research purposes only

**Technical Advice** Recommended protocols and further information about HuCAL recombinant antibody technology can be found in the [HuCAL Antibodies Technical Manual](#)

---

## Related Products

### Recommended Useful Reagents

[LYNX RAPID HRP ANTIBODY CONJUGATION KIT \(LNK001P\)](#)

[LYNX RAPID HRP ANTIBODY CONJUGATION KIT \(LNK002P\)](#)

[LYNX RAPID HRP ANTIBODY CONJUGATION KIT \(LNK003P\)](#)

[LYNX RAPID HRP ANTIBODY CONJUGATION KIT \(LNK004P\)](#)

[LYNX RAPID HRP ANTIBODY CONJUGATION KIT \(LNK005P\)](#)

[LYNX RAPID HRP ANTIBODY CONJUGATION KIT \(LNK006P\)](#)

**North & South** Tel: +1 800 265 7376

**America** Fax: +1 919 878 3751

Email: [antibody\\_sales\\_us@bio-rad.com](mailto:antibody_sales_us@bio-rad.com)

**Worldwide**

Tel: +44 (0)1865 852 700

Fax: +44 (0)1865 852 739

Email: [antibody\\_sales\\_uk@bio-rad.com](mailto:antibody_sales_uk@bio-rad.com)

**Europe**

Tel: +49 (0) 89 8090 95 21

Fax: +49 (0) 89 8090 95 50

Email: [antibody\\_sales\\_de@bio-rad.com](mailto:antibody_sales_de@bio-rad.com)

To find a batch/lot specific datasheet for this product, please use our online search tool at: [bio-rad-antibodies.com/datasheets](https://bio-rad-antibodies.com/datasheets)

'M371631:200612'

**Printed on 23 May 2024**

---

© 2024 Bio-Rad Laboratories Inc | [Legal](#) | [Imprint](#)